This article is more than 5 years old. Information may no longer be current.
VIDEO: Results of faster-acting insulin trials reported
NEW ORLEANS — In this video exclusive, Bruce W. Bode, MD, FACE, president of Atlanta Diabetes Associates, discusses results of the phase 3a Onset clinical trials of faster-acting insulin aspart (Novo Nordisk) vs. insulin aspart (NovoRapid, Novo Nordisk).
Onset 1 compared faster-acting insulin aspart with insulin aspart, both in combination with Levemir (insulin detemir, Novo Nordisk), in adults with type 1 diabetes. Onset 2 compared faster-acting insulin aspart with insulin aspart, both in combination with insulin glargine (Sanofi-Aventis), in adults with type 2 diabetes. Onset 3 compared a basal-bolus regimen with basal insulin therapy, both in combination with metformin.
Faster-acting insulin aspart is the same molecule as insulin aspart with two excipients added: the absorption modifier vitamin B3, or niacinamide, and the amino acid l-arginine as a stabilizer. Compared with insulin aspart, the new formulation appears in the blood in half the time and at twice the levels within 30 minutes and has twice the glucose infusion rate at 30 minutes, according to Bode. Ongoing trials with pump infusion promise even faster action, Bode said.